Structural proteomics: the potential of high-throughput structure determination.
The pharmaceutical industry has embraced genomics as a means to identify new biological targets for target-based drug discovery approaches. Now, genomics is driving a substantial effort in protein structure determination and structure prediction. These structures will provide the opportunity to undertake structure-guided drug discovery programs in the search for new classes of broad-spectrum antibiotics. In addition, these structures could provide structure-based criteria to prioritize certain targets for focused drug discovery programs.
Schmid
Molly B
MB
Affinium Pharmaceuticals, 100 University Avenue, Toronto, Ontario, Canada. mschmid@afnm.com
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis / Q000302:isolation & purification; D000890:Anti-Infective Agents / Q000737:chemistry*; D003461:Crystallography / Q000379:methods; D015195:Drug Design; D023281:Genomics / Q000145:classification / Q000379:methods; D021621:Imaging, Three-Dimensional / Q000379:methods; D015394:Molecular Structure; D010449:Peptide Mapping; D011487:Protein Conformation; D040901:Proteomics / Q000639:trends*; D013678:Technology, Pharmaceutical
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents